Velzatinib (IDRX-42, GSK6042981)
StrateGIST 3
GSK · Phase 3 · Recruiting · Enrollment 450
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Velzatinib 300 mg | GIST after imatinib; excludes KIT/PDGFRA wild type and PDGFRA exon 18 | 300 mg | ITT | sunitinib 50 mg 4/2 | n/r |
| Sunitinib 50 mg 4/2 | GIST after imatinib | 50 mg | ITT | n/r | n/r |
No efficacy figure is in this file for this study.